Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.88 CAD | -2.00% | -2.00% | +13.29% |
Sales 2024 * | 346M 253M | Sales 2025 * | 356M 261M | Capitalization | 608M 445M |
---|---|---|---|---|---|
Net income 2024 * | 2M 1.46M | Net income 2025 * | 13M 9.51M | EV / Sales 2024 * | 1.76 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.71 x |
P/E ratio 2024 * |
210
x | P/E ratio 2025 * |
58.8
x | Employees | 725 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.64% |
Latest transcript on Knight Therapeutics Inc.
1 day | +3.63% | ||
1 month | +3.09% | ||
3 months | +8.50% | ||
6 months | +13.85% | ||
Current year | +15.61% |
Managers | Title | Age | Since |
---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 13-10-31 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 16-06-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 14-01-05 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Robert Lande
BRD | Director/Board Member | 61 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.19% | 11 M€ | -.--% | ||
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 5.88 | -2.00% | 16 693 |
24-05-31 | 6 | +3.63% | 296,481 |
24-05-30 | 5.79 | -3.66% | 48,083 |
24-05-29 | 6.01 | +1.35% | 62,570 |
24-05-28 | 5.93 | -1.17% | 146,128 |
Delayed Quote Toronto S.E., May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.61% | 446M | |
+16.13% | 78.51B | |
+13.10% | 9B | |
+58.17% | 4.96B | |
-14.94% | 4.84B | |
-.--% | 3.72B | |
-26.63% | 2.19B | |
+16.75% | 2.12B | |
-37.97% | 1.94B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock